Novo Nordisk’s Medicare Bridge Mixes Clinical Muscle with a Buyback Boost
The Medicare GLP-1 Bridge program that opens on July 1, 2026, hands Novo Nordisk a potential turning point…
New Weight Loss Drugs Preserve Muscle and Cut Fat
Nearly every pharmaceutical company you can name is chasing this tantalizing idea: hang on to your muscles while…
Novo Nordisk’s Dual Challenge: Building Production Muscle While Proving Pipeline Might
Novo Nordisk stock down 47% as investors eye €1B Italy plant expansion and pivotal Phase 3 CagriSema data…
Menopause Heart Data, Oral Pill Revenue Double, and a Parkinso
Novo Nordisk: Wegovy CV risk reduction 42% in perimenopausal women, oral pill sales double forecasts, high-dose 27.7% weight…